Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration

Metformin is a widely used anti-diabetic drug with potential anti-tumor activity. However, little is known about its global metabolic and transcriptional impacts on tumor cells. In current study, we performed a metabolic profiling on human-derived colon cancer LoVo cells treated by 10 mM metformin for 8, 24 and 48 h. An obvious time-dependent metabolic alteration was observed from 8 to 48 h, prior to the reduction of cell viability. A total of 47, 45 and 66 differential metabolites were identified between control and metformin-treated cells at three time points. Most of the metabolites were up-regulated at 8 h, but down-regulated at 24 and 48 h by metformin. These metabolites were mainly involved in carbohydrates, lipids, amino acids, vitamins and nucleotides metabolism pathways. Meanwhile, the transcirptomic profile revealed 134 and 3061 differentially expressed genes at 8 and 24 h by metformin. In addition to the cancer signaling pathways, expression of genes involved in cell energy metabolism pathways was significantly altered, which were further validated with genes in glucose metabolism pathway. Altogether, our current data indicate that metformin suppressed the proliferation of LoVo cells, which may be due to the modulation on cell energy metabolism at both metabolic and transcriptional levels in a time-dependent way.

[1]  Meiping Guan,et al.  Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients , 2013, PloS one.

[2]  M. McCullough,et al.  Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. , 2010, Gastroenterology.

[3]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[4]  L. Marroquin,et al.  Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. , 2008, Toxicology and applied pharmacology.

[5]  A. Segura‐Carretero,et al.  Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs , 2012, Aging.

[6]  Shih-Chieh Lin,et al.  Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. , 2011, The American journal of pathology.

[7]  C. Bertolotto,et al.  Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. , 2010, Cancer research.

[8]  P. Nangia-Makker,et al.  Metformin: A Potential Therapeutic Agent for Recurrent Colon Cancer , 2014, PloS one.

[9]  G. Stephanopoulos,et al.  Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. , 2013, Cancer research.

[10]  G. Xie,et al.  Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice. , 2012, Journal of proteome research.

[11]  Shailendra Giri,et al.  Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner , 2009, Journal of cellular and molecular medicine.

[12]  H. Kan,et al.  Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[13]  C. Toulas,et al.  Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response , 2015, PloS one.

[14]  T. Kourelis,et al.  Metformin and cancer: new applications for an old drug , 2012, Medical Oncology.

[15]  I. Ben-Sahra,et al.  Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? , 2010, Molecular Cancer Therapeutics.

[16]  Christian M. Metallo,et al.  Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. , 2011, Genes & development.

[17]  R. Veale,et al.  Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones) , 2014, BMC Cancer.

[18]  J. Islamian,et al.  Inhibition of tumor energy pathways for targeted esophagus cancer therapy. , 2015, Metabolism: clinical and experimental.

[19]  M. Gunter,et al.  Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. , 2006, The Journal of nutritional biochemistry.

[20]  G. Pond,et al.  Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK , 2013, British Journal of Cancer.

[21]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[22]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Struhl,et al.  Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[24]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[25]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[26]  Veronica Martinez Marignac,et al.  Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition. , 2015, Journal of cancer research and therapeutics.

[27]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[28]  Joaquín Dopazo,et al.  Paintomics: a web based tool for the joint visualization of transcriptomics and metabolomics data , 2010, Bioinform..

[29]  M. Pollak,et al.  Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria , 2014, The Biochemical journal.

[30]  Y. Choi,et al.  Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells. , 2014, Cancer letters.

[31]  Tianlu Chen,et al.  Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. , 2009, Journal of proteome research.

[32]  Hirokazu Takahashi,et al.  Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinase , 2010, Molecular carcinogenesis.

[33]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[34]  M. Ciriolo,et al.  Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy. , 2014, Biochimica et biophysica acta.

[35]  L. Balluz,et al.  Association Between Diagnosed Diabetes and Self-Reported Cancer Among U.S. Adults , 2011, Diabetes Care.

[36]  D. Xiao,et al.  Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy , 2012, Cell Death and Disease.